Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses elotuzumab, a monoclonal antibody targeting SLAMF7, in relapsed/refractory multiple myeloma. Additionally, Dr Weisel reveals that SLAMF7 is an important target for CAR T-cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть